Sentence examples for microarray platforms had from inspiring English sources

> -wrap-foot> glioblastomatomultiformerme Six different microarray platforms had been used in the studies, with technology from Affymetrix being most frequently used (eight of 13 studies).

In our experimental design, miRNAs not covered by both microarray platforms had a higher likelihood of being false positives or false negatives, with a very small regulated set of miRNAs found shared among both platforms.

121 miRNAs present in both microarray platforms had no detectable measure by small RNA-seq in any of the three biological replicates, whereas 147 detected by small RNA-seq had not been addressed by any of the microarray platforms.

3,972 genes represented in either of the 3 microarray platforms had no detectable measure by DGE in any of the three biological replicates, whereas 130 detected tag sequencing targets had not been addressed by any of the microarray platforms.

It is noteworthy that while all microarray platforms had similar specificity and sensitivity in detecting changes in gene expression, DGE had more false positives, particularly among genes represented by a low number of tags (Additional file 9, Figure S3).

As shown in Figure 1, the two microarray platforms had a concordance of ~9,000 transcripts in the normal setting, but nearly five times more transcripts were detected specifically on the breast tissue specific Breast Cancer DSA microarray platform in the normal and malignant epithelium.

In recent years, genome-wide screening of copy number alterations by comparative genomic hybridization and genomic microarray platforms have revealed a characteristic MCL profile of multiple secondary gains and losses as well as regions of copy number neutral loss of heterozygosity that target mainly genes involved in cell cycle regulation, DNA damage response, and cell survival pathways.

These rice microarray platforms have been successfully used in characterizing gene expression profiles from different tissues and organs (Wang et al.[2010]), different cell types (Jiao et al.[2009]), under biotic and abiotic treatment conditions (Jung et al.[2008b]; Swarbrick et al.[2008]; Jung et al.[2010]), identification of alternative splice (Jung et al.[2009]) and mutants (Bruce et al.[2009]).[2009]

However, no comparative and quality control study of microRNA microarray platforms has been reported yet.

The diversity of microarray platforms has made it a challenge to re-use and/or integrate datasets generated in different experiments to construct array-based diagnostic models.

The large number of commercially available microarray platforms has expanded the use of the technology and made it more widely available to different laboratories.